Dr Lalchandani Labs Ltd
Fundamental Score
Dr Lalchandani Labs Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of DLCL across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (16.83%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Attractive Valuation (P/E: 18.66 vs Industry: 39.28)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (33.33%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Interest Coverage (12.50x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
8 factors identified
Below-Average Return on Equity (3.08%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (2.81%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Limited Growth History (-6.11% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Weak Earnings Growth (-8.59% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (-8.59% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Dr Lalchandani Labs Ltd
About DLCL
Business Overview
Dr Lalchandani Labs Limited provides diagnostic and related healthcare tests and services in India. The company offers doctor consultation, pathology, radiology, hospital lab management, corporate health checkup, and blood bank services, as well as X-ray, TMT, ultrasound, 2D-echo, and medical fitness examinations. It also offers its products online. The company serves individual patients, hospitals and other healthcare providers, and corporate customers. Dr Lalchandani Labs Limited was founded in 1986 and is based in New Delhi, India.
Company Details
Key Leadership
Latest News
DLCL Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Dr Lalchandani Labs Ltd (DLCL)?
As of 29 Jan 2026, 10:34 am IST, Dr Lalchandani Labs Ltd (DLCL) is currently trading at ₹17.58. The stock has a market capitalization of ₹8.77 (Cr).
Is DLCL share price Overvalued or Undervalued?
DLCL is currently trading at a P/E ratio of 18.66x, compared to the industry average of 39.28x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Dr Lalchandani Labs Ltd share price?
Key factors influencing DLCL's price include its quarterly earnings growth (Sales Growth: -3.76%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Dr Lalchandani Labs Ltd a good stock for long-term investment?
Dr Lalchandani Labs Ltd shows a 5-year Profit Growth of -8.59% and an ROE of 3.08%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.45 before investing.
How does Dr Lalchandani Labs Ltd compare with its industry peers?
Dr Lalchandani Labs Ltd competes with major peers in the Healthcare Service Provider. Investors should compare DLCL's P/E of 18.66x and ROE of 3.08% against the industry averages to determine its competitive standing.
What is the P/E ratio of DLCL and what does it mean?
DLCL has a P/E ratio of 18.66x compared to the industry average of 39.28x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹19 for every ₹1 of annual earnings.
How is DLCL performing according to Bull Run's analysis?
DLCL has a Bull Run fundamental score of 4.4/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does DLCL belong to?
DLCL operates in the Healthcare Service Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting Dr Lalchandani Labs Ltd.
What is Return on Equity (ROE) and why is it important for DLCL?
DLCL has an ROE of 3.08%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Dr Lalchandani Labs Ltd generates profits from shareholders' equity.
How is DLCL's debt-to-equity ratio and what does it indicate?
DLCL has a debt-to-equity ratio of 0.45, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is DLCL's dividend yield and is it a good dividend stock?
DLCL offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has DLCL grown over the past 5 years?
DLCL has achieved 5-year growth rates of: Sales Growth -6.11%, Profit Growth -8.59%, and EPS Growth -8.59%.
What is the promoter holding in DLCL and why does it matter?
Promoters hold 31.15% of DLCL shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is DLCL's market capitalization category?
DLCL has a market capitalization of ₹9 crores, placing it in the Small-cap category.
How volatile is DLCL stock?
DLCL has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for DLCL?
DLCL has a 52-week high of ₹N/A and low of ₹N/A.
What is DLCL's operating profit margin trend?
DLCL has a 5-year average Operating Profit Margin (OPM) of 16.83%, indicating the company's operational efficiency.
How is DLCL's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -3.76% and YoY Profit Growth of 33.33%.
What is the institutional holding pattern in DLCL?
DLCL has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.